Company Overview and News

Breakfast briefing: Thursday, September 21

MarketWatch: The S&P 500 and the Dow ended slightly higher on Wednesday, adding to their string of closing records, after the Federal Reserve signalled it expects another interest rate hike by year-end and disclosed timing for reducing its balance sheet. The DJIA rose 41.79 points, or 0.19% to end at 22,412.59, its seventh straight record close. The S&P 500 gained 1.59 points, or 0.06%, to 2,508.24, clocking its sixth record closing high in the last seven sessions.

KLCI slips below 1,720 on regional weakness

2016-04-18 theedgemarkets
KUALA LUMPUR (April 18): The FBM KLCI slipped below the 1,720 point level at mid-morning today in line with the dip at most regional markets.

AHB Holdings jumps 12.2% after being lifted from PN17 list

2016-04-18 theedgemarkets
KUALA LUMPUR (April 18):  AHB Holdings Bhd shares jumped 12.20% this morning after the company was annpounced as no longer a Practice Note No.17 (PN17) as it has regularised its financial condition and level of operations, according to Bursa Malaysia Securities Bhd.

KLCI to start week on positive note, eye 1,730 level

2016-04-17 theedgemarkets
KUALA LUMPUR (April 18): The FBM KLCI is expected to start the week on a positive note today and eye the 1,730-point level.

Lion Corp, CLIQ Energy, Melati Ehsan, AirAsia, Mesiniaga, Brahim’s, Kian Joo, GPA Holdings, Iris Corp and AHB

2016-04-15 theedgemarkets
KUALA LUMPUR (April 15): Based on corporate announcements and news flow today, companies that will be in focus on Monday (April 18) may include: Lion Corp Bhd, CLIQ Energy Bhd, Melati Ehsan Holdings Bhd, AirAsia Bhd, Mesiniaga Bhd, Brahim’s Holdings Bhd, Kian Joo Can Factory Bhd, GPA Holdings Bhd, Iris Corp Bhd and AHB Holdings Bhd.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...